Skip to main content

Risk Reduction

0
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
PUMAN/A1 trial
UTRAN/A1 trial
Active Trials
NCT03935464Completed100Est. Mar 2024
NCT05333679Completed200Est. Jun 2025
Baxter International
1 program
Intensive training groupN/A1 trial
Active Trials
NCT01204619Completed104Est. Mar 2016
Baxter
BaxterCosta Rica - Cartago
1 program
Intensive training groupN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Allergy TherapeuticsUTRA
Allergy TherapeuticsPUMA
Baxter InternationalIntensive training group

Clinical Trials (3)

Total enrollment: 404 patients across 3 trials

Urine Tenofovir Point-of-care Test to Identify Patients in Need of ART Adherence Support (UTRA Study)

Start: Mar 2022Est. completion: Jun 2025200 patients
N/ACompleted

Point-of-care Urine Monitoring of Adherence: Testing a Real-Time Urine Assay of Tenofovir in PrEP

Start: Mar 2021Est. completion: Mar 2024100 patients
N/ACompleted
NCT01204619Baxter InternationalIntensive training group

Trial on Education And Clinical Outcomes for Home PD Patients (TEACH)

Start: Dec 2010Est. completion: Mar 2016104 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.